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Introduction
Countries commit considerable resources to used as drugs, pesticides, food additives,
determine thepotential ofchemicals to cause cosmetics, and industrial processes, or
adverse effects to humans or their envi- those found in consumer products. Specific
ronment. Such efforts apply to chemicals approaches incorporate a series of tests,
This paper was prepared as a joint report for the 13th Meeting of the Scientific Group on Methodologies forthe
Safety Evaluation of Chemicals (SGOMSEC): Alternative Testing Methodologies held 26-31 January 1997 in
Ispra, Italy. Manuscript received at EHP9 May 1997; accepted 20 February 1998.
Address correspondence to Dr. B.J. Blaauboer, RITOX, Utrecht University, PO Box 80.176, 3508 TD Utrecht,
The Netherlands. Telephone: 31 30 2535400 Fax: 31 30 253 50 77. E-mail: b.blaauboer@ritox.dgk.ruu.nI
Abbreviations used: DEREK, deductive estimation of risk from existing knowledge; ECVAM, European
Centre for the Validation of Alternative Methods; MAPREC, molecular analysis by PCR restriction enzyme
cleavage; NIEHS, National Institute of Environmental Health Sciences; PBBK, physiologically based biokinetic;
PCR, polymerase chain reaction; QSAR, quantitative structure-activity relationships; RITOX, Research Institute
of Technology; SAR, structure-activity relationships; SGOMSEC, Scientific Group on Methodologies for the
Safety Evaluation of Chemicals.
commonly involving laboratory animals,
to first ascertain the potential ofa chemical
to cause an arrayoftoxic effects, e.g., ocular
toxicity, infertility, nervous disorders, can-
cer, etc. The array oftoxic end points, and
relevant protocols to detect such effects, are
usually determined by regulatory agencies,
based on the recommendation oftheir own
scientists or ad hoc groups of scientific
experts. Thus, the nature oftesting evolves
with advances in scientific knowledge; new
end points maybe identified or refinements
proposed for methods used to assess previ-
ously selected end points. The overall goal
is to devise strategies that prevent adverse
impacts on the health of the public and
the environment.
AlternativeTest Methodsfor
the Protection of Human
Health andthe Environment
Risk assessment refers to a structured
sequence ofanalyses by which one reviews
and characterizes the potential toxic prop-
erties of a chemical. Such analyses usually
incorporate separate but integrated judg-
ments based on qualitative and quanti-
tative criteria. The qualitative process
identifies the type and quantity of infor-
mation needed and then reviews and
integrates that information to reach a
judgement as to the potential ofa chemical
to cause adverse effects. In rendering a
qualitative judgment, one determines that
there are adequate data to conclude that an
adverse effect has been observed or could be
anticipated and, ifnot in the species ofcon-
cern, that the effect may occur in the sub-
jects of concern, i.e., humans, ecosystems,
etc. The subsequent step employs proce-
dures that express the potential of the
chemical to cause such effects at specified
levels ofexposure, with particular focus on
the lowest doses that cause such effects and
the changes in incidence or severity of the
effectswith increasing dose.
Manyofthe toxicology tests in common
use today were designed and modified
according to clinical andphysiological crite-
ria selected on the basis ofthe commonality
ofthe observation, e.g., organ dysfunction,
cancer, infertility, or birth defects, rather
than understanding the underlying patho-
biology of the process. Thus, tests were
empirical and acceptance was based on
correlationwith observations in humans.
Alternatives to these empirical tests have
been developed to recapitulate critical steps
or events in the disease process leading to
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the adverse response. These events may
represent the mechanism of action or one
of a cascade ofevents, often referred to as
the mode ofaction, between exposure and
the expression of disease. The fidelity of
these isolated events for prediction of the -
end-stage disease ranges from poor to excel-
lent. A desired property ofalternative tests,
or batteries thereof, is that they should sup-
port decisions as to toxicity on the basis of
the composite of information. Individual
test results should contribute to a profile of
data such that the confidence in a test result
can be enhanced or minimized on the basis
ofcorroborative findings. Thus, test results
can be used in a correlative sense to recapit-
ulate the expected results from a test system
such as awhole animalwith all physiological
processes intact.
Advances in general scientific knowl-
edge mayindicate the need to either expand
the breadth of data collected or refine the
type of data sought. Refinements in test
procedures result in the collection of data
that provides a better understanding ofthe
factors associated with the development of
an effect, rather than merely recording the
presence and severityofsuch effect.
Over theyears there has been agrowing
ethical and legal commitment to modify
test strategies so as to result in the use of
fewer animals as well as to modify pro-
cedures to be more sensitive to the welfare
of the animals used in testing. Tiered
approaches have been developed that are
more efficient in cost and time and that
also result in reduction, refinement, or
replacement of animals in test schemes.
Although visible progress has occurred in
regulatory agencies, advances of at least
similar magnitude have also been realized
in commercial settings. Alternative meth-
ods have been used to predict the toxicity
ofsynthesized intermediates ordegradation
products during the development of new
products. Such applications benefit worker
safety and the public by highlighting the
need to limit exposure or by deciding not
to develop certain material for commercial
use. This represents disease prevention-
the preferred public health goal.
In developing alternative test method-
ologies, one must be responsive to changes
in the type oftest data that are ofvalue to
the risk assessment process and to the data
that provide the best guidance for product
development. A strategy might entail the
development ofa series ofin vitro tests that
model the steps leading to the emergence of
toxic effects in humans. Simple steps will be
explored at first, leading to the development
ofsystems ofincreasing sophistication. The
success of simple systems, e.g., receptor-
binding assays, suggests that a series oftests
could be successfully developed, perhaps in
a tiered manner. Such an approach may
have particular utility in refining or sup-
planting repeat-dose toxicity tests or even
the complexities of carcinogenicity or
developmental toxicitytesting.
The development of a successful alter-
native test must go beyond the definition of
a test protocol that provides consistency of
results of appropriate specificity and sensi-
tivity. It must also include a process in
which test data can be converted to a form
that can be used in the assessment or
characterization of the toxic end point of
interest. This may take a variety of forms
ranging from a classification scheme to a
measure of dose response, e.g., potency.
Bruner et al. (1) have proposed the use of
statistical methods to evaluate the predictive
potential of assay methods such as ocular
irritation or skin sensitization. Bristol et al.
(2) have used an empirical approach to the
prospective evaluation ofmethods proposed
to predict potential carcinogens.
Progress in Development and
Acceptance ofAlternative
Methods
Advances in new technologies and under-
standing of biological and chemical phe-
nomena have enhanced the development
and acceptance of alternative test methods
over the past fewyears. The development of
new tests continues to be driven by consid-
erations ofscientific credibility, the concept
of reduction, refinement and replacement
ofanimal use, and the desire for faster and
less expensive methods. New test methods
often reflect new knowledge of molecular
biology and an increased level of scientific
usefulness. The process for development of
a new test method is more scientifically
rigorous than in the past, resulting in
increased likelihood that new tests will
improve the qualityofriskassessment.
Data from new tests are more likely to
be useful to help build quantitative struc-
ture-activity relationships (QSARs) or
other models because ofbetter understand-
ing of the scientific basis for the tests.
Importantly, QSAR models thereby
become more predictive ofbiological activ-
ity and can be the basis for developing
hypotheses about mechanisms of toxicity.
Because ofbetter understanding ofthe bio-
logical basis ofnewtests, theyare more eas-
ily integrated into predictive strategies and
risk assessment strategies. Development of
new test methods has extended into areas of
toxicology beyond those of earlier focus,
that is, skin and eye irritation and skin cor-
rosion. Alternative tests for prediction of
carcinogenicity have received particular
attention in recent years. Thus, new tests
are developed today on the basis of
improved mechanistic understanding in tox-
icology, the need for quantitative data for
hazard identification and risk assessment,
the need for test results to contribute to a
profile of information for risk assessment,
and the need for data to be extrapolated to
the species ofchoice.
The increased use ofcomputer software
programs in areas ofcomputational chem-
istry and various statistical and modeling
procedures has made it possible to relate
many aspects of chemical structure to
observed biological and toxicological effects.
It also made these tools more widely avail-
able. This has impacted the development of
QSAR and other models that relate chemi-
cal exposure levels to tissue concentrations
oftoxicants and theassociated toxiceffects.
MecanisticApproaches
There is currendy much talkofthe need for
mechanistic tests, although it is not always
clear what is meant by this term. For exam-
ple, it could describe tests that involve bio-
logical systemswith a mechanistic basis that
is understood, or tests that are able to iden-
tify effects that are mechanistically related
to the in vivoeffects to be predicted.
A mechanism has been defined as an
explanation of an observed phenomenon
that explains the processes underlying the
phenomenon in terms of events at lower
levels oforganization (3). Thus, a mecha-
nistic test is based on a system at an accept-
able level of organization and a relevant
end point based on a sufficient understand-
ing ofthe cellular and/or molecular basis of
the effect under consideration. An example
is a test based on interaction with a defined
receptor, which is a critical or pivotal stage
in the development ofan effect.
Fidelity, Discrimination, Analogy,
Mechanism, and Correlation. Fidelity is
the accuracy with which a model repro-
duces the overall properties of what is
being modeled, whereas discrimination is
the accuracy with which a model repro-
duces a particular property or properties of
what is being modeled. No model can offer
100% fidelity or 100% discrimination, but
the best models will have the highest possi-
ble fidelity in combination with the highest
possible discrimination. In general, a low
fidelity/high discrimination model is more
Environmental Health Perspectives * Vol 106, Supplement 2 * April 1998 414CONCEPTUAL ISSUES
likely to be useful than a high fidelity/low
discrimination model (4).
The assumed relevance ofanimal tests to
humans is based on the general high fidelity
of animal models, i.e., on analogy (where
similarity in a particular circumstance is
inferred from agreement or similarity in an
acceptable number ofother features in the
systems being compared), and not on
mechanism (where similarity is based on an
adequate knowledge of the mechanistic
basis ofthe phenomenon under considera-
tion and its operation in the systems being
compared). In any case, similarity does not
mean identity, sojudgment in the interpre-
tation of the meaning of data will always
be necessary, whatever the model may be.
Correlative approaches, based solely on
statistical relationships between phenomena
that cannot be explained on a mechanistic
basis, are unlikely to lead to correlative
nonanimal tests that will receive widespread
acceptance. Thiswill applyevenwhere such
tests would be more useful than existing
animal tests that also lacked a sufficient
mechanistic basis.
Some qualitative and quantitative struc-
ture-activity relationship (SAR) models
generally represent correlative approaches;
but mechanistic SAR approaches are also
being developed, e.g., when interactions
with specific receptors can be predicted
from structure and the consequences of
such interactions are understood (see also
the section on QSAR).
High Fidelity andMechanistic Tests.
There can be confusion overwhether ahigh
fidelity test is a mechanistic test. For exam-
ple, the use ofwhole rat embryos in vitro
is an example of a high fidelity model,
since the cultured embryos are very similar
to rat embryos in utero. Thus, when whole
embryo cultures are used to screen chemi-
cals for teratogenicity (according to a num-
ber of specified, relevant end points), we
have a high fidelity test, but we do not have
a sufficient understanding ofthe cellular or
molecular basis ofteratogenicity for this to
be termed a mechanistic test.
Mechanistic tests are the tests that are
most likely to be high discrimination
tests, but the fidelity of the system must
also be borne in mind. For example, the
Salmonella typhimurium test is considered
to be a relatively high discrimination test
for genotoxicity, but a liver S9 fraction
must be incorporated to improve its
fidelity, i.e., its ability to detect metabolism-
mediated genotoxicity.
It is commonly believed that validation
is the limiting step in the acceptance of
new test methods. However, it is now
becoming clear that, in fact, the main lim-
iting factor is new test development. The
development ofrelevant and reliable mecha-
nistic toxicity tests must depend on the rate
of progress achieved in the fundamental
science oftoxicology.
Existing Tests, New Tests, and
KnowledgeNeededc Because the data from
an animal test are themselves of limited
usefulness in terms of the purpose of the
test, e.g., for predicting particular likely
effects in human beings, those data must
also be oflimited utility as a basis for eval-
uating the reliability ofin vitrotest data for
predicting the likelihood ofthose effects in
human beings.
It is essential to have a regular, thor-
ough, and objective review ofall test meth-
ods in light ofthe purposes for which they
are used. This, in turn, requires an objective
analysis ofthose purposes. Ifit is our aim to
use tests to provide essential knowledge as a
means ofdeveloping the safest, most effec-
tive products, we must first define more
precisely the knowledge needed to make
this possible. If another aim is to develop
valid nonanimal test procedures, we must
decide how these new test procedures
should be validated. If the existing animal
test can be shown to be reliable and relevant
in providing the knowledge needed, then
data from that test can be used in the vali-
dation of potential replacement alternative
methods. Ifnot, then no attempt should be
made to use such data in the validation of
new tests. In those circumstances, the way
forward is to establish a convincing rela-
tionship between the information that can
be provided by the nonanimal test proce-
dure and the knowledge needed to predict
likelyeffects in human beings.
Another problem in new test develop-
ment and validation is related to the avail-
ability of sufficient high quality data
about the in vivo effects of an adequate
number and range of chemicals. Some
biological data, particularly data generated
prior to the advent of Good Laboratory
Practices (GLP), do not meet today's strin-
gent requirements for acceptability. In
some cases it may be possible to use QSARs
to upgrade these data so that they are
acceptable for use in the development and
validation of alternative tests. If QSAR
techniques can be used to demonstrate that
the results ofthese tests are consistent with
the physicochemical attributes of the
chemicals when compared with the results
from tests conforming to the current accep-
tance criteria, they should be acceptable for




The development ofcomputer-based meth-
ods of assimilating and analyzing diverse
chemical properties provides the opportu-
nity to create algorithms for predicting toxi-
cological effects of congeneric chemicals.
One method that has been extensively
developed is QSAR based on the premise
that the properties ofa chemical are implicit
in its molecular structure. As a consequence,
ifa mechanistichypothesis can be proposed
linking a group ofrelated chemicals with a
particular toxic end point, the hypothesis is
then used to define relevant parameters to
establish a structure-activity relationship.
The resulting model is then tested, and the
hypothesis and parameters refined, until an
adequate model is obtained. For a QSAR
to bevalidandreliable, thedependent prop-
erty for all ofthe chemicals covered by the
relationship has to be elicited by a mecha-
nism that is both common and relevant to
thatdependent property (5).
The principles ofQSARs also need to be
applied to the development ofin vitro alter-
natives to animal tests ifthose methods are
to be reliable. Historically these principles
have been overlooked in many cases with
unfortunate results. Some alternative tests
determine end points that are substantially
different from those they claim to predict
because the mechanism modeled by the in
vitro alternative represents only part ofthat
which is active in vivo. In other cases, tests
have been developed that can predict end
points accurately for some dasses ofchemi-
cals, but are then wrongly assumed to be
applicable to all chemical classes. The fact
that different types ofchemicals may elicit
changes in a particular biological end point
via different mechanisms has clearly not
been appreciated.
It has long been recognized that for a
chemical to be biologically active, it must
first be transported from its site ofadmin-
istration to its site ofaction (partition) and
it must then bind to or react with its
receptor or target (reactivity). If any
QSAR or in vitro model is deficient in
modeling either partition or reactivity,
only a partial correlation with the in vivo
response is likely to be observed, e.g., the
varying degrees of partial correlation with
in vivo data found with the many in vitro
methods that have been developed and
advocated as alternatives to the Draize rab-
bit eye irritation test (6). Thus, it follows
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that for an in vitro test to reliably predict in
vivo toxic potential, it should be sensitive to
the same parameters that are responsible for
the effects in vivo; such a test would be
expected to showahigh degreeofcorrelation
with the response in vivo.
One example ofthe use ofa mechanistic
approach in SAR is provided by the expert
system DEREK (thedeductive estimation of
risk from existing knowledge). DEREK uses
rules based on correlations between the
structure of chemicals and their toxico-
logical activity, supported by the knowledge
of organochemical reaction mechanisms.
Examples ofphysicochemical-based QSARs
are the models forskin corrosivity oforganic
acids, bases, phenols, andelectrophiles (5).
A recurring feature ofQSAR models for
the classification oftoxicological hazard is
the problem of biological uncertainty at
boundary regions. The concept of the
boundary region has its origin in the fact
that most regulatory schemes operate ini-
tially by quantizing continuous biological
(toxicological) data into discrete hazard
bands that can conveniently be used in the
regulatory process. It is the biological vari-
ability inherent in toxicological testing that
leads to uncertainty in classification in the
boundary regions. This variability could
manifest itselfas the results oftwo well-con-
ducted Draize rabbit eye irritation tests on
the same chemical leading to a nonirritant
dassification in one case and an irritant das-
sification in the other. Away from the
boundary region, the inherent biological
variability is less likely to result in two sepa-
rate tests leading to different dassifications.
QSAR techniques such as principal compo-
nents analysis afford visualization and hence
predictability of regions ofchemical para-
meter space in which ambiguity in in vivo
results mayarise.
There are three ways in which to select
a set of chemicals for the validation of an
alternative method:
* Make a selection ofchemicals that guar-
antees success (all of the chemicals are
farawayfrom classification boundaries).
* Make a selection that guarantees failure
(all ofthe chemicals are on or close to a
classification boundary).
* Select the chemical objectively, by trying
to retain balance among the various
mechanistic types, between dassification
categories, and between classification
categories in each mechanistic type.
The use of principal components
mapping allows the selection ofchemicals
that cover the widest possible parameter
space in terms of both biological activity
and physicochemical properties. Tech-
niques ofthis type have been used in con-
nection with the selection oftest chemicals





Understanding the absorption, distribution,
metabolism, and excretion (i.e., the bioki-
netics) of toxic chemicals is necessary to
predict the target organ concentrations of
the chemical or its active metabolite(s).
Putting this dynamic information into a
mathematical framework, or model, allows
the prediction of target organ concentra-
tions ofchemicals after exposure. In physi-
ologically based kinetic modeling a number
of physiological parameters (such as blood
flows, organ volumes) and chemical-specific
parameters (e.g., tissue solubility, biotrans-
formation rates) are combined, which
allows the prediction oforgan or tissue con-
centrations of chemicals, given a certain
external dose. These model parameters can
in many cases be derived from in vitro data
or from calculations on the basis ofphysico-
chemical properties ofthe compound under
study and its metabolite(s). This is espe-
cially the case for the calculation oftissue-
blood partition coefficients. A number of
examples can be given for the calculation
ofcritical tissue concentrations on the basis
of physiologically based biokinetic models
(PBBK) (8).
PBBK allows the integration of data
derived from relevant in vitro toxicity tests
in an assessment ofa compound's systemic
toxicity. If, for instance, the neurotoxicity
of a compound can be measured in cell
cultures, the minimal effective concentra-
tion for the compound can be used as the
input for the tissue concentration in the
PBBK model. This will then allow the cal-
culation of the corresponding dose.
However, such an approach implies that
the relevant mechanism of toxicity is pre-
sent in the in vitrosystem.
Other important advantages of PBBK
models are the use ofhuman blood levels
of chemicals in an exposure-risk assess-
ment and their application to interspecies
extrapolation. Because a model can be
constructed for any species for which the
physiological parameter (blood flow, organ
volume, etc.) is available, data empirically
determined in one species can be trans-
lated to another. This offers the possibility
to make a more realistic choice of the
species studied, leading to a better design
of toxicological studies. Similarly, extra-
polations for different dose ranges and
routes of administration of chemicals are
possible. Even if not all necessary data are
available based on in vitro or other nonan-
imal-based data, the application ofmodels
partly based on experiments with a limited
number of animals is of great value in
reducing the number of animal studies
needed. It also can be helpful in the most
economical design of animal studies by
giving the appropriate concentrations to
be studied (8).
Application ofMolecularBiology
New methods in the field of molecular
biology have permitted the development
of animal models with genetic alterations
that are specific for new test methods.
This involves introducing or deleting
genetic material to make the animal
resemble the human more closely or to
make the animal more sensitive and spe-
cific for a type oftoxicity such as carcino-
genicity (9). Significant progress has been
achieved over the past two decades in
defining elements of chemical structure
and results of genotoxicity tests that pre-
'dict chemical-induced carcinogenicity.
Although much has been achieved, both
product development and public health
decisions rely upon obtaining bioassay
results. The search must continue for more
effective methods ofassessing the carcino-
genic potential of substances, which can
contribute to safety assessment decisions.
The rapid and substantial rate of progress
in molecular and cell biology and genetics
has resulted in both new knowledge ofspe-
cific genes that are involved in the induc-
tion and development ofcancers in rodents
and humans, and oftechniques using such
genes as specific targets for the action of
potential carcinogens. These advances in
knowledge will continue to provide new
models and systems to improve drug and
chemical safety assessments.
Recent developments in methodologies
to complement or supplant long-term car-
cinogenicity bioassays include transgenic
mouse models. These models use unique
phenotypic properties imposed either by
pronuclear injection of specifically regu-
lated oncogenes or via knock-out of a
tumor-suppressor gene. Properties of the
transgenic models that make them most
appropriate as bioassays are as follows:
They provide for appropriate disposi-
tion and metabolism oftest agents: they
provide specific genotypic targets and
phenotypic responses to exposures.
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* They provide the end point of direct
interest (e.g., tumor development).
* Single species can minimize the conse-
quences of strain- or species-specific
effects encountered in long-term conven-
tional bioassays by significandy reducing
the time to response to 6 months.
* The influence ofspontaneous tumors is
minimized.
* The short duration of exposure and
uniformity of responses allow for a sig-
nificant reduction in the number ofani-
mals needed to perform abioassay (9).
Because significant advances in molecu-
lar biology and transgenic models continue
at a rapid pace, the current models may be
viewed as prototypes, but their use can
provide valuable information on the prop-
erties of specific chemicals as well as pro-
viding a database with which any future
transgenic models can be efficiently com-
pared. The p53-deficient, Tg.AC, and
rasHII models are currently being evalu-
ated through a multilaboratory interna-
tional effort that will result in a database of
40 to 50 chemicals by the end of 1997.
The evaluation effort involves the use of
known positive controls tested in all partic-
ipating laboratories, together with unique
agents tested in selected laboratories, but
with a group of carcinogenic and noncar-
cinogenic substances tested in common in
all three models. Since the chemicals are
drawn mostly from substances that have
undergone rodent carcinogenicity bioassay
by the U .S. National Toxicology Program,
a direct comparison within and between
the assays is achieved. In addition, chemi-
cals undergoing conventional carcinogenic-
ity bioassays can be used to prospectively
evaluate the transgenic models. Because a
mechanistic basis can be inferred for the
transgenic models, information on chemi-
cal structure, genetic, or systemic toxicity,
or other properties can be used to predict
the outcome of the prospective assay. It is
also possible to analyze tumors induced in
the transgenic lines for transgene expres-
sion or for the induction of mutations.
Such data can contribute to both further
verification ofthe models as well as provide
additional information on the specific





The trend toward alternative methods will
undoubtedly lead to a wider variety of
approaches to hazard prediction and risk
assessment. This will be due to the much
greater range of technologies and methods
that will have to be applied. Often, data
provided byvarious methods will have to be
combined and integrated as contributions to
the overall decisionmaking process. This, in
turn, will lead to the need for a wider range
of equipment, expertise, and experience.
These new approaches will be effective only
if they result in integrated, stepwise, and
tier-testing strategies, aimed at giving the
most relevant, reliable, and useful outcomes
quicklyand inexpensively (10).
These new methods, new skills, and
new strategies will require training pro-
grams to provide personnel, and data banks
to provide ready access to test protocols,
prediction models, outcomes ofvalidation
studies, and evidence ofexperience in use.
Ideally, this approach would be based on
international cooperation, leading to the
greater harmonization oftest guidelines and
to agreement on the principles ofvalidation
and acceptance ofalternative methods.
The development of unnecessary tests
must be avoided. The need for a new test
in relation to other tests that could provide
the same sort ofinformation should be sat-
isfactorily established at an early stage of
test development.
Integration into aStrategy
In a toxicological risk assessment it is logical
to take into consideration information
from all available sources. How this is done
is highly dependent on the goal ofthe risk
assessment process. In many cases it is sub-
ject to the judgment of the person con-
ducting the exercise. Such information
can include animal data, epidemiological
data, mechanistically based information
derived from in vitro models, or computer-
generated data. Examples from several of
these approaches are cited in accompanying
documents (4,5,8,9).
For the introduction of new method-
ologies, it is important to clarify how the
methods can be incorporated into an inte-
grated approach. For example, a test
employing cell cultures will not be easily
interpreted in terms of the systemic toxic-
ity of a compound without taking into
consideration the biokinetics of the com-
pound or its metabolites. It will thus be
possible to link the external dose with the
appropriate in vitro toxicity data and make
predictions on the toxicity of the com-
pound under study. Taken together, these
approaches will result in test strategies that
lead to prediction ofa compound's toxicity
while reducing the reliance on strategies
solelybased on the use ofanimals.
Criteria ofAcceptance:
Lessonsfrom Examples
An example of the application of advances
in molecular biology to alternative methods
is the development oftwo methods for neu-
rovirulence testing of modified live oral
polio vaccines. For more than 40 years,
monkeys have been used to test batches of
this vaccine for neurovirulence. This test is
expensive, labor intensive, and requires a
large number of animals. The World
Health Organization (WHO) has com-
pleted a collaborative study on the use of
the molecular analysis by polymerase chain
reaction (PCR) and restriction enzyme
cleavage (MAPREC) assay. This assay is
based on quantification of revertants at
position 472 ofthe 5' noncoding region of
the poliovirus genome, which has been
shown to produce neurovirulence in the
monkey test (11). Studies have demon-
strated the usefulness of the MAPREC
assay as a screening test to predict neurovir-
ulence. Positive results in this assay are now
considered to be predictive of neuroviru-
lence and therefore eliminate the need for
additional testing in monkeys.
A transgenic mouse model (Tg PVR)
that is susceptible to the poliovirus has
been developed by introduction of the
human gene that codes for the cellular
receptors to poliovirus into the mouse
genome. This mouse model develops clini-
cal signs and morphological lesions in the
central nervous system similar to those in
primates when infected with neurovirulent
poliovirus strains. Recent studies (11) have
demonstrated that this mouse model is as
sensitive as the monkey test and can be
considered a potential replacement for the
monkey test. This example further demon-
strates the potential for applying molecular
biology techniques to new alternative
test methodologies.
Summary
Substantial resources are being committed
worldwide in the search for alternatives to
the use of animals for the protection of
human health and the environment. Such
commitment demands strong scientific
stewardship of resources. Concomitantly, it
must be recognized that the search is an
ongoing process that must intrinsically be
driven by new knowledge emanating from
fundamental research in toxicology, carcino-
genesis, molecular biology, biochemistry,
computer sciences, and a host of other
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disciplines. Progress is bestachieved through
international cooperation and harmoniza-
tion that is based upon critical evaluation
and strong scientific consensus. In this way
the most useful alternative methods will
emerge for the safety assessment ofdrugs,
chemicals, andenvironmental factors.
Recommendations
* The rate of development of alternative
tests for use in toxicological assessment
should be increased.
* An increased emphasis should be placed
on the development ofmechanism-based
methods forspecific aspects oftoxicity.
* Investment should be increased in the
development of fundamental research
that underpins toxicology and toxicity
testing.
* Training institutions, granting bodies,
and regulatory agencies should be
encouraged to support research and
training that will enhance the develop-
ment and use ofalternative systems.
* Accepted alternative methods should be
integrated into toxicity assessment of
chemicals.
* International cooperation in develop-
ment, validation, and acceptance ofalter-
native methods shouldbeencouraged.
* In the interest of the most effective
development and use of alternative
methods, international harmonization
of chemical toxicity classification
schemes shouldbe encouraged.
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